BioSpace News Archive

Drug Development

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics Ltd. today announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis.

July 31, 2023
·
4 min read
FDA

FDA Authorizes Marketing of MAGENTIQ-COLO™, a Cutting-Edge AI Gastrointestinal Lesion Software Detection System that Helps Detect Lesions in Real Time During Colonoscopy Procedures

MAGENTIQ-EYE LTD., an Israeli-based technology company founded in 2014, announced today that the U.S. Food and Drug Administration (FDA) has cleared the MAGENTIQ-COLO™ via the 510(k) process.

July 31, 2023
·
3 min read
Business

Akeso Inc. Published 2023 Interim Results Positive Profit Alert

Akeso Inc. announced that it is expected that the Company will record a profit of not less than RMB2.3 billion for the six months ended June 30, 2023.

July 31, 2023
·
3 min read
Policy

U.S. FDA Accepts Biologics License Application for GC Biopharma’s GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

GC Biopharma, a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, announced that the U.S. Food and Drug Administration has accepted the Company’s resubmission of the Biologics License Application for its GC5107B for patients with primary humoral immunodeficiency.

July 31, 2023
·
2 min read
Pharm Country

OKYO Pharma Limited Announces Withdrawal of Public Offering - July 31, 2023

OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, announced the withdrawal of its proposed public offering of ordinary shares.

July 31, 2023
·
2 min read
Drug Development

Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)

Biosion USA, Inc., a global clinical-stage R&D biotechnology company, announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis .

July 31, 2023
·
2 min read
Business

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Fennec Pharmaceuticals Inc. announced that the Company will release its second quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, August 3, 2023.

July 31, 2023
·
2 min read
Business

Quarterly Activities and Cashflow Report - July 31, 2023

Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

July 31, 2023
·
8 min read
Business

Boundless Bio Appoints Jami Rubin as Chief Financial Officer

Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA for patients with oncogene amplified cancers, announced the appointment of Jami Rubin as Chief Financial Officer.

July 31, 2023
·
3 min read
Business

OmniAb to Report Second Quarter 2023 Financial Results on August 10

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

July 31, 2023
·
2 min read